- Home
- LPRO vs ABOS Comparison
LPRO vs ABOS Comparison
Compare LPRO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | ABOS |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 155.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPRO | ABOS |
|---|---|---|
| Price | $1.35 | $3.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $2.83 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 451.8K | 324.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.86 |
| 52 Week High | $4.79 | $3.41 |
Technical Indicators
Market Signals| Indicator | LPRO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 72.70 |
| Support Level | $1.33 | $1.21 |
| Resistance Level | $1.96 | N/A |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 27.66 | 91.35 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.